The changing ‘steroid metabolome’ across the spectrum of non-alcoholic fatty liver disease

Ahmad Moolla1, Amin Amin2, Bev Hughes2, Wiebke Arlt2, Zaki Hassan-Smith2, Matt Armstrong3, Philip Newsome3, Tahir Shah4, Luc Van Gaal4, An Verrijken4, Sven Francque4, Michael Biehi5, Jeremy Tomlinson1

1Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK; 2Centre for Endocrinology, Diabetes & Metabolism, University of Birmingham, UK; 3Centre for Liver Research, University of Birmingham, UK; 4University of Antwerp, Belgium; 5University of Groningen, The Netherlands

INTRODUCTION & OBJECTIVES

Dysregulated glucocorticoid (GC) metabolism has been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). NAFLD extends from simple steatosis, to inflammation (steatohepatitis / NASH), fibrosis and cirrhosis. It is the hepatic manifestation of the metabolic syndrome and is independently associated with liver and cardiovascular mortality. Liver biopsy – which is both invasive and resource intensive – remains the gold standard diagnostic tool, and lifestyle induced weight loss achieved through diet and exercise remains the current mainstay of treatment for NAFLD.

GC availability to bind and activate the GC-receptor is controlled at the pre-receptor level by a series of enzymes that are able to regenerate or inactive cortisol. Specifically, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inactive cortisone to cortisol and thus amplifies local GC action. In contrast, the A-ring reductases (5α-reductase type 1 and 2 and 5β-reductase) clear cortisol to its inactive dihydro-metabolites.

The liver represents the major site of steroid hormone metabolism within the body. Previous studies have suggested dynamic changes in NAFLD, but have only been performed in very small numbers of patients within defined histological groups1-2.

Better characterisation and understanding of these steroid hormone pathways may well yield novel targets for intervention and improved non-invasive diagnostic markers, and help to define better staging and treatment strategies for NAFLD.

METHODS

To investigate changes to the pathways which regulate the bioavailability of cortisol, we recruited 39 subjects with biopsy proven NASH, 44 subjects with biopsy proven cirrhosis and 58 healthy controls without known liver disease.

All subjects provided a spot urine sample for analysis alongside collection of clinical data. Urinary steroid metabolites were analysed using gas chromatography / mass spectrometry (GC/MS). Steroid metabolite data were corrected for urinary creatinine.

Computational analysis of the steroid metabolome was performed employing generalized matrix learning vector quantisation (GMLVQ) to identify steroids that have the ability to discriminate between the different groups.

RESULTS

Demographic data are presented in Table 1. Mean age in those with NASH was lower (p<0.0001) in comparison to the other groups. There were more females in the control group compared to the other groups. Those with NASH had a significantly higher BMI (p<0.0001).

<table>
<thead>
<tr>
<th>Table 1:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Gender m/f</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
</tbody>
</table>

Total cortisol (F) metabolites were significantly raised in those with NASH compared to controls. In contrast, total cortisol (F) metabolites in those with cirrhosis were significantly reduced when compared to controls (Fig. 1).

11β-HSD1 activity – reflected by the (THF+5α-THF) / THF ratio – was similar in those with NASH and controls but was significantly increased in those with cirrhosis (p<0.0001) (Fig. 2). 5α-reductase activity – reflected by the THF/5α-THF ratio – did not differ across the 3 groups (p=0.09) (Fig.3).

Generalised machine learning vector quantisation (GMLVQ) analysis allowed complete separation of control and cirrhosis groups (Fig 4a) with an AUC ROC of 0.99 (Fig 4b).

CONCLUSIONS

Glucocorticoid metabolic pathways are complex systems which share substrates and products. Through this work, we have identified specific dysregulated pathways in cortisol metabolism that appear differentially regulated across the spectrum of non-alcoholic fatty liver disease, which provides an insight into its pathophysiology.

Examining steroid metabolism using an unbiased ‘whole system’ model, offers considerable potential in providing a non-invasive assessment of staging and monitoring liver disease alongside the identification of novel discrete targets for intervention in non-alcoholic fatty liver disease.

REFERENCES


This work was supported through a Novo Nordisk Clinical Research Fellowship and the NIHR Oxford Biomedical Research Centre.

173-GP
Receptors & Signaling
Ahmad Moolla